Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis
Cell Reports · 2023-08 · 42 (8) · 112944
DOI: 10.1016/j.celrep.2023.112944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-08. Verfasst von Xinyue Ma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong 250012, P.R. China; Gynecology Oncology Key Laborator…. Hauptthemen laut MEDLINE: Interferon-beta, CD8-Positive T-Lymphocytes, Endometrial Neoplasms, Microsatellite Instability. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapies display clinical efficacy in microsatellite instable (MSI) endometrial cancer (EC) treatment, the key mechanism of which is reversing T cell exhaustion and restoration of anti-tumor immunity. Here, we demonstrate that transcription factor 19 (TCF19), one of the most significantly differentially expressed genes between MSI and microsatellite stable (MSS) patients in The Cancer Genome Atlas (TCGA)-EC cohort, is associated with poor prognosis and immune exhaustion signature. Specifically, TCF19 is significantly elevated in MSI EC, which in turn promotes tripartite motif-containing 14 (TRIM14) transcription and correlates with hyperactive signaling of the TANK-binding kinase 1 (TBK1)-interferon regulatory factor 3 (IRF3)-interferon β (IFN-β) pathway. The TCF19-TRIM14 axis promotes tumorigenicity under non-immunological background, and the enhanced downstream secretion of IFN-β facilitates CD8+ T cell exhaustion through cell differentiation reprogramming. Finally, using humanized models, we show that a combination of TCF19 inhibition and ICB therapy demonstrates more effective anti-tumor responses. Together, our study indicates that targeting TCF19 is a potent strategy for alleviating CD8+ T cell exhaustion and synergizing with ICB in tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong 250012, P.R. China; Gynecology Oncology Key Laboratory, Qilu Hospital of Shandong University, Ji'nan, Shandong 250012, P.R.…
- Department of Pathology, Northwestern University, Chicago, IL 60208, USA.
Zitieren
APA
Ma, X., Wang, Q., Sun, C., Agarwal, I., Wu, H., Chen, J., Zhao, C., Qi, G., Teng, Q., Yuan, C., Yan, S., Peng, J., Li, R., Song, K., Zhang, Q., & Kong, B. (2023). Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis. Cell Reports, 42(8), 112944. https://doi.org/10.1016/j.celrep.2023.112944
Vancouver
Ma X, Wang Q, Sun C, Agarwal I, Wu H, Chen J, et al. Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis. Cell Reports. 2023;42(8):112944. doi:10.1016/j.celrep.2023.112944
BibTeX
@article{Ma2023,
author = {Ma, Xinyue and Wang, Qiuman and Sun, Chenggong and Agarwal, Indu and Wu, Huan and Chen, Jingying and Zhao, Chen and Qi, Gonghua and Teng, Qiuli and Yuan, Cunzhong and Yan, Shi and Peng, Jiali and Li, Rongrong and Song, Kun and Zhang, Qing and Kong, Beihua},
title = {Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {8},
pages = {112944},
doi = {10.1016/j.celrep.2023.112944}
}
EUVIMED